Current medical and surgical management of Raynaud's syndrome

    Research output: Contribution to journalArticle

    24 Scopus citations

    Abstract

    Raynaud's syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. A number of pharmacologic and invasive therapies have been studied to treat RS symptoms; however, there are no specific treatments that are currently approved by the U.S. Food and Drug Administration specifically for RS. Of the available pharmacologic agents, calciumchannel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied and found to be efficacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have been found to be universally beneficial, although the phosphodiesterase V inhibitors have been gaining in popularity. Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is summarized.

    Original languageEnglish (US)
    Pages (from-to)1710-1716
    Number of pages7
    JournalJournal of vascular surgery
    Volume57
    Issue number6
    DOIs
    StatePublished - Jun 2013

    ASJC Scopus subject areas

    • Surgery
    • Cardiology and Cardiovascular Medicine

    Fingerprint Dive into the research topics of 'Current medical and surgical management of Raynaud's syndrome'. Together they form a unique fingerprint.

  • Cite this